A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced Otezla® tablet formulations to assure comparability of results from Phase III trials of BI 730357 (new oral agent for treatment of psoriasis as well as other T helper 17 cells (Th17)-mediated diseases) regardless of whether only the EU-sourced Otezla® or EU and US-sourced Otezla®/Japan-sourced Otezla® have been used as an active comparator.
Epistemonikos ID: 5697e6c5b76b4325bf48cafdbd4c88f22eeb882b
First added on: May 08, 2024